A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy
- Study Title
- An Open-Label, Long-Term Safety, Tolerability, and Efficacy Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (Open RECLAIM-DCP)
- Teva Identifier
- TV50717-CNS-30081 | 2019-001807-19
- ClinicalTrials.gov Identifier
- NCT04200352
- Study Status
- Terminated
- Trial Condition(s)
- Cerebral Palsy, Dyskinetic
- Interventions
- Drug: TEV-50717
- EudraCT Number
- 2019-001807-19
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child, Adult
- Age Range
- 6 Years to 18 Years
- Trial Duration
- February 04, 2020 - February 14, 2023
- Phase
- Phase 3
Additional info
Study Type
InterventionalLocation - Where to Participate
You may contact 1-888-483-8279 or email USMedInfo@tevapharm.com to obtain more information about study locations.